About Us
About Carna
Management
Our Business
Products & Services
Products
Kinase Proteins
Biotinylated Kinases
Kinase Protein Assay Kits
Substrates
Stable Cell Lines
Services
Profiling Services
NanoBRET™ TE Intracellular Kinase Cell-Based Assay Services
Protein-Protein Interactions
Live-cell Kinase Assays
ClariCELL™ Kinase Cell-Based Assay Services
Crystallization Services
Custom Production of Ultra-Pure Proteins for Crystallography
Weak Affinity Chromatography (WAC™)
Pricing & Technical Inquiry
Drug Discovery
Pipeline
Science
Technology
Partnering
Investors
News
Financial Reports/Presentations
Financial Highlights
IR Schedule
IR Contact
JP
EN
JP
EN
Kinase Inhibitor Discovery
with an untiring quest for future therapeutics
Our Business
Products & Services
Drug Discovery
Latest News
Dec 08, 2020
Investors
Revision of Results Forecast for the Fiscal Year Ending December 31, 2020
Nov 09, 2020
Investors
Financial Results FY2020Q3
Nov 09, 2020
Investors
Consolidated Financial Results for the Third Quarter of the Year Ending December 31, 2020
Aug 25, 2020
Investors
Carna announces the initiation of dosing in a First-in-Human Phase 1 study of AS-0871
Aug 25, 2020
Drug Discovery
Carna announces the initiation of dosing in a First-in-Human Phase 1 study of AS-0871.
Aug 11, 2020
Investors
Financial Results FY2020Q2
Aug 07, 2020
Investors
Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2020
Jun 25, 2020
Investors
Carna Biosciences Reacquires Worldwide Rights to Develop and Commercialize AS-0141
About Us
Investors
Investor Contact
Products & Services Contact